Danish biotech Bavarian Nordic files for a $86 million IPO

Bavarian Nordic, which is developing vaccines that stimulate a t-cell response to fight infectious diseases and cancers, filed on Monday with the SEC to raise up to $86 million in an initial public offering.

The Kvistgaard, Denmark-based company, which was founded in 1992 and booked $187 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol BAVN. Bavarian Nordic filed confidentially on 10/19/2015. Cowen & Company, Piper Jaffray and Nomura Securities are the joint bookrunners on the deal. No pricing terms were disclosed.